Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Kate Bingham, Chair, UK Vaccine Task Force
John Reed, Executive Vice President, Global Head of Research & Development, Sanofi
Carol Gallagher, Pharm. D., Venture Partner, NEA
Henry Gosebruch, Executive Vice President, Chief Strategy Officer, Abbvie
Sheila Gujrathi, M.D., Co-Founder, Chief Executive Officer, Gossamer Bio
Jason Hafler, Managing Director, Sanofi Ventures
Richard Heyman, Ph.D., Venture Partner, Arch Ventures; Founder and Executive Chairman of the Board, Metacrine Inc.
Nina Kjellson, General Partner/West Coast, Canaan
Carole Nuechterlein, Head, Roche Venture Fund
Ioannis Sapountzis, Ph.D, Corporate Senior Vice President, Business Development, Boehringer Ingelheim Pharmaceuticals, Inc.
Nigel Sheail, Global Head, Mergers & Acquisitions and Business Development & Licensing, Novartis
Uwe Schoenbeck, Ph.D, Senior Vice President and Chief Scientific Officer, Emerging Science and Innovation (ES&I), Pfizer Worldwide Research, Development, and Medical
Andrew Schwab, Managing Partner, 5am Ventures
Armen Shanafelt, Ph.D., General Partner, Lilly Ventures
Alex Szidon, Vice President and Head of Business Development for gRED, Genentech
Ben Thorner, SVP and Head of BD&L, Merck
Jeffrey Warmke, Ph.D, Senior Vice President, Search and Evaluation & Alliance Management, Global Business Development, Daiichi Sankyo